<p>AngioDynamics, Inc.（納斯達克代碼：ANGO - 獲取免費報告）在週一的交易中，股價突破了其 200 日移動平均線。該股票的 200 日移動平均線為 9.88 美元，最高交易價為 11.95 美元。AngioDynamics 的股票最後交易價為 11.82 美元，成交量為 396,477 股。</p>
<p>獲取 <strong>AngioDynamics</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位股票研究分析師最近對該公司進行了評論。HC Wainwright 在 7 月 16 日的研究報告中重申了對 AngioDynamics 的 “買入” 評級，並給出了 16.00 美元的目標價。Canaccord Genuity Group 將 AngioDynamics 的目標價從 17.00 美元上調至 18.00 美元，並在 10 月 3 日的研究報告中給予該公司 “買入” 評級。Wall Street Zen 在 10 月 4 日的研究報告中將 AngioDynamics 的評級從 “買入” 下調至 “持有”。Lake Street Capital 在 7 月 16 日的研究報告中開始覆蓋 AngioDynamics，給予 “買入” 評級和 24.00 美元的目標價。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 AngioDynamics 的 “賣出（d-）” 評級。三位股票研究分析師對該股票給予了 “買入” 評級，一位分析師則給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，平均目標價為 19.33 美元。</p>
<p><strong>查看我們對 AngioDynamics 的最新分析</strong></p>
<h2>AngioDynamics 股票上漲 2.4%</h2>
<p>該股票的市值為 4.8698 億美元，市盈率為-15.15，貝塔值為 0.78。該公司有 50 日簡單移動平均線為 10.53 美元，200 日簡單移動平均線為 9.88 美元。</p>
<p>AngioDynamics（納斯達克代碼：ANGO - 獲取免費報告）最近在 10 月 2 日公佈了其財報。這家醫療器械供應商報告本季度每股收益（EPS）為-0.10 美元，超出分析師一致預期的-0.12 美元，超出幅度為 0.02 美元。AngioDynamics 的股本回報率為-3.16%，淨利潤率為-10.67%。該公司本季度的收入為 7571 萬美元，而分析師預期為 7269 萬美元。去年同期，該公司的每股收益為-0.11 美元。該公司的收入同比增長 12.1%。AngioDynamics 已將其 2026 財年的指導目標設定為每股收益-0.330 至-0.230 美元。分析師平均預測 AngioDynamics, Inc.在當前財年將發佈每股收益-0.37 美元。</p>
<h2>AngioDynamics 的內部買賣情況</h2>
<p>在其他 AngioDynamics 的新聞中，首席執行官 James C. Clemmer 在 10 月 9 日的交易中購買了 10,000 股 AngioDynamics 股票。該股票的平均購買成本為每股 11.15 美元，總價值為 111,500.00 美元。交易完成後，首席執行官持有該公司 882,529 股股票，價值為 9,840,198.35 美元。此次交易使其持股比例增加了 1.15%。該收購在向證券交易委員會提交的文件中披露，文件可通過此鏈接訪問。公司內部人士持有該公司 6.00% 的股票。</p>
<h2>機構投資者對 AngioDynamics 的看法</h2>
<p>幾家對沖基金最近調整了對該公司的持股。Squarepoint Ops LLC 在第二季度將其在 AngioDynamics 的持股增加了 28.3%。Squarepoint Ops LLC 目前持有 85,696 股醫療器械供應商的股票，價值為 850,000 美元，此前在該期間內又購買了 18,879 股。懷俄明州購買了 AngioDynamics 的新股份，價值約為 31,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 AngioDynamics 的持股增加了 359.0%。Tower Research Capital LLC TRC 目前持有 5,457 股醫療器械供應商的股票，價值為 54,000 美元，此前在上個季度又購買了 4,268 股。Manatuck Hill Partners LLC 在第二季度將其在 AngioDynamics 的持股增加了 7.7%。Manatuck Hill Partners LLC 目前持有 350,000 股醫療器械供應商的股票，價值為 3,472,000 美元，此前在上個季度又購買了 25,000 股。最後，Massar Capital Management LP 在第二季度收購了 AngioDynamics 的新股份，價值為 278,000 美元。89.43% 的股票由機構投資者持有。</p>
<h2>關於 AngioDynamics</h2>
<p>（獲取免費報告）</p>
<p>AngioDynamics, Inc.是一家醫療技術公司，專注於設計、製造和銷售用於治療外周血管疾病、腫瘤和外科環境的醫療、外科和診斷設備。該公司提供的 Auryon 動脈切除系統旨在提供優化的波長、脈衝寬度和幅度，以去除病變，同時保護血管壁內皮。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 AngioDynamics 更好</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>路易威登財報顯示奢侈品牛市尚未結束</li>
<li>初學者如何閲讀股票圖表</li>
<li>3 只高收益銀行供投資者在下跌時購買</li>
<li>使用 MarketBeat 股息税計算器</li>
<li>5 只意外受益於未來機器人熱潮的股票</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 AngioDynamics 嗎？</h2>
<p>在考慮 AngioDynamics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 AngioDynamics 並不在名單上。</p>
<p>雖然 AngioDynamics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

阿吉奧動態

<p>AngioDynamics（納斯達克代碼：ANGO）股票已超過其 200 日移動平均線，交易價格為 11.82 美元。分析師的評級不一，HC Wainwright 維持 “買入” 評級，目標價為 16.00 美元，而 Weiss Ratings 則給出了 “賣出” 評級。該公司報告的收入同比增長 12.1%，最近的每股收益為（0.10 美元），超出預期。首席執行官 James C. Clemmer 以每股 11.15 美元購買了 10,000 股。機構投資者持有 89.43% 的股份，反映出強烈的投資興趣。平均目標價為 19.33 美元，儘管面臨當前挑戰，仍顯示出潛在的增長空間</p>

<p>AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.88 and traded as high as $11.95. AngioDynamics shares last traded at $11.82, with a volume of 396,477 shares changing hands.</p>
<div class="lb-trans"><p>AngioDynamics, Inc.（納斯達克代碼：ANGO - 獲取免費報告）在週一的交易中，股價突破了其 200 日移動平均線。該股票的 200 日移動平均線為 9.88 美元，最高交易價為 11.95 美元。AngioDynamics 的股票最後交易價為 11.82 美元，成交量為 396,477 股。</p>
</div><p>Get <strong>AngioDynamics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>AngioDynamics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several equities research analysts recently commented on the company. HC Wainwright reissued a &#34;buy&#34; rating and issued a $16.00 price target on shares of AngioDynamics in a research note on Wednesday, July 16th. Canaccord Genuity Group boosted their price target on AngioDynamics from $17.00 to $18.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 3rd. Wall Street Zen cut AngioDynamics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, October 4th. Lake Street Capital assumed coverage on AngioDynamics in a research note on Wednesday, July 16th. They issued a &#34;buy&#34; rating and a $24.00 price target for the company. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $19.33.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該公司進行了評論。HC Wainwright 在 7 月 16 日的研究報告中重申了對 AngioDynamics 的 “買入” 評級，並給出了 16.00 美元的目標價。Canaccord Genuity Group 將 AngioDynamics 的目標價從 17.00 美元上調至 18.00 美元，並在 10 月 3 日的研究報告中給予該公司 “買入” 評級。Wall Street Zen 在 10 月 4 日的研究報告中將 AngioDynamics 的評級從 “買入” 下調至 “持有”。Lake Street Capital 在 7 月 16 日的研究報告中開始覆蓋 AngioDynamics，給予 “買入” 評級和 24.00 美元的目標價。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 AngioDynamics 的 “賣出（d-）” 評級。三位股票研究分析師對該股票給予了 “買入” 評級，一位分析師則給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，平均目標價為 19.33 美元。</p>
</div><p><strong>View Our Latest Analysis on AngioDynamics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 AngioDynamics 的最新分析</strong></p>
</div><h2>AngioDynamics Stock Up 2.4%</h2>
<div class="lb-trans"><h2>AngioDynamics 股票上漲 2.4%</h2>
</div><p>The stock has a market cap of $486.98 million, a P/E ratio of -15.15 and a beta of 0.78. The business has a 50-day simple moving average of $10.53 and a 200-day simple moving average of $9.88.</p>
<div class="lb-trans"><p>該股票的市值為 4.8698 億美元，市盈率為-15.15，貝塔值為 0.78。該公司有 50 日簡單移動平均線為 10.53 美元，200 日簡單移動平均線為 9.88 美元。</p>
</div><p>AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The firm had revenue of $75.71 million during the quarter, compared to analysts' expectations of $72.69 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. The company's revenue was up 12.1% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. On average, analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>AngioDynamics（納斯達克代碼：ANGO - 獲取免費報告）最近在 10 月 2 日公佈了其財報。這家醫療器械供應商報告本季度每股收益（EPS）為-0.10 美元，超出分析師一致預期的-0.12 美元，超出幅度為 0.02 美元。AngioDynamics 的股本回報率為-3.16%，淨利潤率為-10.67%。該公司本季度的收入為 7571 萬美元，而分析師預期為 7269 萬美元。去年同期，該公司的每股收益為-0.11 美元。該公司的收入同比增長 12.1%。AngioDynamics 已將其 2026 財年的指導目標設定為每股收益-0.330 至-0.230 美元。分析師平均預測 AngioDynamics, Inc.在當前財年將發佈每股收益-0.37 美元。</p>
</div><h2>Insider Buying and Selling at AngioDynamics</h2>
<div class="lb-trans"><h2>AngioDynamics 的內部買賣情況</h2>
</div><p>In other AngioDynamics news, CEO James C. Clemmer acquired 10,000 shares of AngioDynamics stock in a transaction dated Thursday, October 9th. The stock was bought at an average cost of $11.15 per share, with a total value of $111,500.00. Following the completion of the transaction, the chief executive officer owned 882,529 shares of the company's stock, valued at $9,840,198.35. The trade was a 1.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.00% of the company's stock.</p>
<div class="lb-trans"><p>在其他 AngioDynamics 的新聞中，首席執行官 James C. Clemmer 在 10 月 9 日的交易中購買了 10,000 股 AngioDynamics 股票。該股票的平均購買成本為每股 11.15 美元，總價值為 111,500.00 美元。交易完成後，首席執行官持有該公司 882,529 股股票，價值為 9,840,198.35 美元。此次交易使其持股比例增加了 1.15%。該收購在向證券交易委員會提交的文件中披露，文件可通過此鏈接訪問。公司內部人士持有該公司 6.00% 的股票。</p>
</div><h2>Institutional Investors Weigh In On AngioDynamics</h2>
<div class="lb-trans"><h2>機構投資者對 AngioDynamics 的看法</h2>
</div><p>Several hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC boosted its position in shares of AngioDynamics by 28.3% in the second quarter. Squarepoint Ops LLC now owns 85,696 shares of the medical instruments supplier's stock valued at $850,000 after acquiring an additional 18,879 shares during the period. State of Wyoming bought a new stake in shares of AngioDynamics in the second quarter valued at approximately $31,000. Tower Research Capital LLC TRC raised its stake in shares of AngioDynamics by 359.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock valued at $54,000 after purchasing an additional 4,268 shares in the last quarter. Manatuck Hill Partners LLC raised its stake in shares of AngioDynamics by 7.7% in the second quarter. Manatuck Hill Partners LLC now owns 350,000 shares of the medical instruments supplier's stock valued at $3,472,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Massar Capital Management LP acquired a new position in shares of AngioDynamics in the second quarter valued at $278,000. 89.43% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金最近調整了對該公司的持股。Squarepoint Ops LLC 在第二季度將其在 AngioDynamics 的持股增加了 28.3%。Squarepoint Ops LLC 目前持有 85,696 股醫療器械供應商的股票，價值為 850,000 美元，此前在該期間內又購買了 18,879 股。懷俄明州購買了 AngioDynamics 的新股份，價值約為 31,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 AngioDynamics 的持股增加了 359.0%。Tower Research Capital LLC TRC 目前持有 5,457 股醫療器械供應商的股票，價值為 54,000 美元，此前在上個季度又購買了 4,268 股。Manatuck Hill Partners LLC 在第二季度將其在 AngioDynamics 的持股增加了 7.7%。Manatuck Hill Partners LLC 目前持有 350,000 股醫療器械供應商的股票，價值為 3,472,000 美元，此前在上個季度又購買了 25,000 股。最後，Massar Capital Management LP 在第二季度收購了 AngioDynamics 的新股份，價值為 278,000 美元。89.43% 的股票由機構投資者持有。</p>
</div><h2>About AngioDynamics</h2>
<div class="lb-trans"><h2>關於 AngioDynamics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.</p>
<div class="lb-trans"><p>AngioDynamics, Inc.是一家醫療技術公司，專注於設計、製造和銷售用於治療外周血管疾病、腫瘤和外科環境的醫療、外科和診斷設備。該公司提供的 Auryon 動脈切除系統旨在提供優化的波長、脈衝寬度和幅度，以去除病變，同時保護血管壁內皮。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than AngioDynamics</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet</li>
<li>How to Read Stock Charts for Beginners</li>
<li>3 High-Yield Banks for Investors to Buy on the Dip</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>5 Surprising Stocks Set to Benefit From a Future Robotics Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 AngioDynamics 更好</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>路易威登財報顯示奢侈品牛市尚未結束</li>
<li>初學者如何閲讀股票圖表</li>
<li>3 只高收益銀行供投資者在下跌時購買</li>
<li>使用 MarketBeat 股息税計算器</li>
<li>5 只意外受益於未來機器人熱潮的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AngioDynamics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 AngioDynamics 嗎？</h2>
</div><p>Before you consider AngioDynamics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 AngioDynamics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 AngioDynamics 並不在名單上。</p>
</div><p>While AngioDynamics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 AngioDynamics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

AngioDynamics（NASDAQ:ANGO）的股價已超過 200 日移動平均線 - 現在是賣出的時候嗎？